APC/Cyanine7 anti-mouse CD4 Antibody APC/Cyanine7 anti-mouse CD4 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

BALB/c mouse thymocytes

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with APC/Cyanine7 under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Red Laser (633 nm)

Application Notes

The RM4-5 antibody blocks the binding of GK1.5 antibody and H129.19 antibody to CD4⁺ T cells, but not RM4-4 antibody. Additional reported applications (for the relevant formats) include: blocking of ligand binding, in vivo depletion of CD4⁺ cells¹, and immunohistochemistry of acetone-fixed frozen tissue sections^2,3,11 and paraffin-embedded sections¹¹. Clone RM4-5 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. Instead, acetone frozen or zinc-fixed paraffin sections are recommended. The Ultra-LEAF™ Purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100575 and 100576).

Application References

1. Kruisbeek AM. 1991. In Curr. Protocols Immunol. pp. 4.1.1-4.1.5. (Block, Deplete)
2. Nitta H, et al. 1997. Cell Vision 4:73. (IHC)
3. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045.
4. Muraille E, et al. 2003. Infect. Immun. 71:2704. (IHC)
5. León-Ponte M, et al. 2007. Blood 109:3139. (FC)
6. Bourdeau A, et al. 2007. Blood doi:10.1182/blood-2006-08-044370. (FC)
7. Matsumoto M, et al. 2007.J. Immunol.178:2499. PubMed
8. Shigeta A, et al. 2008. Blood 112:4915. PubMed
9. Zaborsky N, et al. 2010. J. Immunol. 184:725. PubMed
10. Rodrigues-Manzanet R, et al. 2010. P. Natl Acad Sci USA 107:8706. PubMed
11. Whiteland JL, et al. 1995. J. Histochem. Cytochem. 43:313. (IHC)

Product Citations

1. Jarick KJ, et al. 2018. Front Immunol. 9:1468. PubMed
2. Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed
3. Ho HM, et al. 2022. Pharmaceutics. 14:. PubMed
4. Ke F, et al. 2023. Elife. 12:. PubMed
5. Rundberg Nilsson A, et al. 2023. iScience. 26:106341. PubMed
6. Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed
7. Kfoury Y, et al. 2021. Cancer Cell. 39:1464. PubMed
8. Schnell A, et al. 2021. Cell. 184:6281. PubMed
9. Guttman O, et al. 2022. J Cell Biol. 221: . PubMed
10. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
11. Kim JS, et al. 2023. J Biol Chem. 299:102886. PubMed
12. Xiao R, et al. 2022. J Immunol. 208:2109. PubMed
13. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
14. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
15. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
16. Ma F, et al. 2020. Cell Death Dis. 1.172222222. PubMed
17. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
18. Pokrovskii M, et al. 2020. EMBO J. 39:e104159. PubMed
19. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
20. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
21. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
22. Pan H, et al. 2020. Mol Psychiatry. . PubMed
23. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
24. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
25. Guo HF, et al. 2021. Commun Biol. 4:482. PubMed
26. Wei M, et al. 2014. Protein Eng Des Sel. 27:289. PubMed
27. Cuburu N, et al. 2019. J Immunol. 202:1250. PubMed
28. Westfall S, et al. 2020. Brain Behav Immun. . PubMed
29. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
30. Shiomi A, et al. 2014. J Immunol. 193:849. PubMed
31. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
32. Synn CB, et al. 2022. Clin Transl Immunology. 11:e1364. PubMed
33. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
34. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
35. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
36. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
37. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
38. Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed
39. Tan X, et al. 2021. Sci Adv. 7: . PubMed
40. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
41. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
42. Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed
43. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
44. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
45. Saigusa R, et al. 2018. Arthritis Res Ther. 20:23. PubMed
46. Boehm DT, et al. 2019. NPJ Vaccines. 4:40. PubMed
47. Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed
48. Dionisio-Santos DA, et al. 2021. Front Neurosci. 15:758677. PubMed
49. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
50. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
51. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
52. Clement CC, et al. 2021. Immunity. 54:721. PubMed
53. Brenndörfer E, et al. 2014. J Immunol. 192:1671. PubMed
54. Weng Q, et al. 2018. Cell Regen (Lond). 7:7. PubMed
55. Koide S, et al. 2022. iScience. 25:103603. PubMed
56. Yokomizo-Nakano T, et al. 2020. Cancer Res. 80:2523. PubMed
57. Yun H, et al. 2020. Immunity. 53(5):1050-1062.e5. PubMed
58. Ulrich V, et al. 2016. EMBO Mol Med. 8: 643 - 653. PubMed
59. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
60. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
61. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
62. Aryal B, et al. 2016. Nat Commun. 7:12313. PubMed
63. Kumar R, et al. 2020. Cell Reports. 30(8):2512-2525. PubMed
64. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
65. Howie D, et al. 2019. Front Immunol. 10:1860. PubMed
66. Cobbold SP, et al. 2018. Front Immunol. 9:1381. PubMed
67. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
68. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed
69. Jarick KJ, et al. 2018. Front Immunol. 9:1468. PubMed
70. Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed
71. Ho HM, et al. 2022. Pharmaceutics. 14:. PubMed
72. Ke F, et al. 2023. Elife. 12:. PubMed
73. Rundberg Nilsson A, et al. 2023. iScience. 26:106341. PubMed
74. Mabire M, et al. 2023. Nat Commun. 14:1830. PubMed
75. Kfoury Y, et al. 2021. Cancer Cell. 39:1464. PubMed
76. Schnell A, et al. 2021. Cell. 184:6281. PubMed
77. Guttman O, et al. 2022. J Cell Biol. 221: . PubMed
78. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
79. Kim JS, et al. 2023. J Biol Chem. 299:102886. PubMed
80. Xiao R, et al. 2022. J Immunol. 208:2109. PubMed
81. Xiong W, et al. 2022. Nat Commun. 13:1700. PubMed
82. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
83. Turner JS et al. 2018. Cell reports. 25(6):1395-1403 . PubMed
84. Ma F, et al. 2020. Cell Death Dis. 1.172222222. PubMed
85. Tordesillas L, et al. 2018. Nat Commun. 9:5238. PubMed
86. Pokrovskii M, et al. 2020. EMBO J. 39:e104159. PubMed
87. Acharya N, et al. 2020. Immunity. 53(3):658-671.e6. PubMed
88. Ogawa C et al. 2018. Cell reports. 25(1):19-28 . PubMed
89. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
90. Pan H, et al. 2020. Mol Psychiatry. . PubMed
91. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
92. Peng L, et al. 2020. Transl Lung Cancer Res. 0.892361111. PubMed
93. Guo HF, et al. 2021. Commun Biol. 4:482. PubMed
94. Wei M, et al. 2014. Protein Eng Des Sel. 27:289. PubMed
95. Cuburu N, et al. 2019. J Immunol. 202:1250. PubMed
96. Westfall S, et al. 2020. Brain Behav Immun. . PubMed
97. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
98. Shiomi A, et al. 2014. J Immunol. 193:849. PubMed
99. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
100. Synn CB, et al. 2022. Clin Transl Immunology. 11:e1364. PubMed
101. Taniguchi H, et al. 2022. Cell Rep. 39:110814. PubMed
102. Mencarelli A, et al. 2016. Sci Rep. 6:30802. PubMed
103. Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed
104. Witkowski MT, et al. 2020. Cancer Cell. 37:867. PubMed
105. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
106. Mender I, et al. 2020. Cancer Cell. 38(3):400-411.e6. PubMed
107. Tan X, et al. 2021. Sci Adv. 7: . PubMed
108. Lu X, et al. 2015. J Immunol. 194:2011. PubMed
109. Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed
110. Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed
111. Biton M et al. 2018. Cell. 175(5):1307-1320 . PubMed
112. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
113. Saigusa R, et al. 2018. Arthritis Res Ther. 20:23. PubMed
114. Boehm DT, et al. 2019. NPJ Vaccines. 4:40. PubMed
115. Lou Y, et al. 2021. Int J Mol Sci. 22:. PubMed
116. Dionisio-Santos DA, et al. 2021. Front Neurosci. 15:758677. PubMed
117. Chen RJ, et al. 2022. iScience. 25:105595. PubMed
118. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
119. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
120. Clement CC, et al. 2021. Immunity. 54:721. PubMed
121. Brenndörfer E, et al. 2014. J Immunol. 192:1671. PubMed
122. Weng Q, et al. 2018. Cell Regen (Lond). 7:7. PubMed
123. Koide S, et al. 2022. iScience. 25:103603. PubMed
124. Yokomizo-Nakano T, et al. 2020. Cancer Res. 80:2523. PubMed
125. Yun H, et al. 2020. Immunity. 53(5):1050-1062.e5. PubMed
126. Ulrich V, et al. 2016. EMBO Mol Med. 8: 643 - 653. PubMed
127. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
128. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
129. Ding Z, et al. 2017. Sci Rep. 10.1038/s41598-017-12488-z. PubMed
130. Aryal B, et al. 2016. Nat Commun. 7:12313. PubMed
131. Kumar R, et al. 2020. Cell Reports. 30(8):2512-2525. PubMed
132. Guo Y, et al. 2021. Nat Immunol. 22:746. PubMed
133. Howie D, et al. 2019. Front Immunol. 10:1860. PubMed
134. Cobbold SP, et al. 2018. Front Immunol. 9:1381. PubMed
135. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
136. Gonzalez-Figueroa P, et al. 2021. Cell. 184(7):1775-1789.e19. PubMed

RRID

AB_312726 (BioLegend Cat. No. 100525)
AB_312727 (BioLegend Cat. No. 100526)

Antigen Details

Structure

Ig superfamily, 55 kD

Distribution

Majority of thymocytes, T cell subset

Function

TCR co-receptor, T cell activation

Ligand/Receptor

MHC class II molecule

Cell Type

Dendritic cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules

Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID

12504 View all products for this Gene ID

UniProt

View information about CD4 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.

TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.

Other Formats

Certificate of Analysis